Related Experiment Videos
Novel chemotherapeutic agents in clinical development
1Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada.
Current Opinion in Oncology
|December 1, 1991
Summary
Seven novel chemotherapeutic agents targeting various mechanisms are in clinical development for cancer treatment. Their ultimate clinical utility hinges on efficacy demonstrated in comparative trials.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- The pursuit of novel chemotherapeutic agents aims for improved efficacy and safety.
- Existing treatments necessitate the development of drugs with unique mechanisms and better therapeutic indexes.
Purpose of the Study:
- To review seven novel chemotherapeutic agents in various stages of clinical development.
- To highlight their distinct chemical properties and mechanisms of action.
Main Methods:
- Review of preclinical and clinical data for seven selected agents.
- Description of mechanisms including enzyme inhibition, DNA incorporation, and microtubule stabilization.
Main Results:
- D1694 (thymidylate synthase inhibitor) shows preclinical promise.
- Anthrapyrazoles (e.g., CI-941) demonstrate clinical activity in breast cancer.
- Lometrexol, Taxotere, Gemcitabine, BMY-25067, and Topotecan are in various clinical trial phases with distinct targets and preliminary findings.
Conclusions:
- These novel agents possess unique characteristics warranting clinical investigation.
- Long-term clinical roles will be determined by outcomes in Phase III comparative trials.